Search results
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patient With Severe Stiff-Person Syndrome...
Lodi News-Sentinel· 2 days ago"It is extremely encouraging to see this patient improving...
EU regulator mandates label updates on CAR-T cancer therapies
Reuters· 5 days agoThe European health regulator said on Friday product information for a class of cancer therapies...
EHA 2024: Roche’s Columvi competes in BiTE battle with positive results in DLBCL
Pharmaceutical Technology via Yahoo Finance· 2 days agoBased on the latest STARGLO trial results, there is potential to extend Columvi into earlier lines...
12 recent scientific breakthroughs
The Week via Yahoo News· 15 hours agoFood and Drug Administration (FDA) approved the first cellular therapy for aggressive forms of melanoma. The treatment, called Amtagvi, is "designed to...
Mozart Therapeutics doses first patients in trial of MTX-101 for autoimmune diseases
Clinical Trials Arena via Yahoo Finance· 1 day agoUS-based biopharmaceutical company Mozart Therapeutics has dosed the first subjects in its Phase...
Innovent Reports Oncology Pipeline Updates at Investor Meeting
Morningstar· 7 hours agoSAN FRANCISCO and SUZHOU, China, June 18, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou...
Morningstar· 4 days agoNEW YORK, June 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.
Caribou Biosciences, Inc. (NASDAQ:CRBU) Short Interest Up 9.7% in May
ETF DAILY NEWS· 6 hours agoCaribou Biosciences, Inc. (NASDAQ:CRBU – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 11,510,000 ...
Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias...
WWTI Watertown· 5 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
Age is just a number: Immune cell 'epigenetic clock' ticks independently of organism lifespan
Medical Xpress· 7 days agoScientists at St. Jude Children's Research Hospital and the University of Minnesota investigated the unique 'epigenetic clock' of T cell aging, demonstrating ...